Autobahn Therapeutics, a biotechnology company developing restorative treatments for people affected by neuropsychiatric and neuroimmunologic disorders, today announced the initiation of a Phase 2 ...
Adults with attention-deficit/hyperactivity disorder, or ADHD, who use an extended-release medication are more likely to continue the treatment and have a lower risk of developing substance use ...